| Year |
Citation |
Score |
| 2024 |
Follmann D, Mateja A, Fay MP, Magaret CA, Huang Y, Fong Y, Angier H, Nason M, Gay CL, Kotloff K, Woo W, Cho I, Dunkle LM. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 38372392 DOI: 10.1093/cid/ciae081 |
0.328 |
|
| 2023 |
Moliva JI, Andrew SF, Flynn BJ, Wagner DA, Foulds KE, Gagne M, Flebbe DR, Lamb E, Provost S, Marquez J, Mychalowych A, Lorag CG, Honeycutt CC, Burnett MR, McCormick L, ... ... Nason MC, et al. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates. Biorxiv : the Preprint Server For Biology. PMID 38076895 DOI: 10.1101/2023.11.22.567930 |
0.346 |
|
| 2023 |
Gagne M, Flynn BJ, Andrew SF, Flebbe DR, Mychalowych A, Lamb E, Davis-Gardner ME, Burnett MR, Serebryannyy LA, Lin BC, Pessaint L, Todd JM, Ziff ZE, Maule E, Carroll R, ... ... Nason MC, et al. Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates. Biorxiv : the Preprint Server For Biology. PMID 37986823 DOI: 10.1101/2023.11.06.565765 |
0.38 |
|
| 2023 |
Gagne M, Flynn BJ, Honeycutt CC, Flebbe DR, Andrew SF, Provost SJ, McCormick L, Van Ry A, McCarthy E, Todd JM, Bao S, Teng IT, Marciano S, Rudich Y, Li C, ... ... Nason MC, et al. RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways. Biorxiv : the Preprint Server For Biology. PMID 37503026 DOI: 10.1101/2023.06.09.544432 |
0.312 |
|
| 2022 |
Longini IM, Yang Y, Fleming TR, Muñoz-Fontela C, Wang R, Ellenberg SS, Qian G, Halloran ME, Nason M, Gruttola V, Mulangu S, Huang Y, Donnelly CA, Henao Restrepo AM. A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. Clinical Trials (London, England). 17407745221110880. PMID 35866633 DOI: 10.1177/17407745221110880 |
0.345 |
|
| 2022 |
Houser KV, Gaudinski MR, Happe M, Narpala S, Verardi R, Sarfo EK, Corrigan AR, Wu R, Rothwell RS, Novik L, Hendel CS, Gordon IJ, Berkowitz NM, Cartagena CT, Widge AT, ... ... Nason M, et al. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. Eclinicalmedicine. 48: 101477. PMID 35783486 DOI: 10.1016/j.eclinm.2022.101477 |
0.361 |
|
| 2022 |
Casazza JP, Cale EM, Narpala S, Yamshchikov GV, Coates EE, Hendel CS, Novik L, Holman LA, Widge AT, Apte P, Gordon I, Gaudinski MR, Conan-Cibotti M, Lin BC, Nason MC, et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine. PMID 35411076 DOI: 10.1038/s41591-022-01762-x |
0.306 |
|
| 2021 |
Corbett KS, Nason MC, Flach B, Gagne M, O'Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science (New York, N.Y.). 373: eabj0299. PMID 34529476 DOI: 10.1126/science.abj0299 |
0.307 |
|
| 2021 |
Corbett KS, Gagne M, Wagner DA, Connell SO, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham C, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, ... ... Nason MC, et al. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. Biorxiv : the Preprint Server For Biology. PMID 34426813 DOI: 10.1101/2021.08.11.456015 |
0.301 |
|
| 2021 |
Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, ... ... Nason MC, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science (New York, N.Y.). PMID 34385356 DOI: 10.1126/science.abj4176 |
0.326 |
|
| 2021 |
Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, Kolluri A, Marte-Salcedo O, Imeru A, Nason M, Ding LK, Decederfelt H, Duan J, Neal J, Raiten J, et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature. PMID 34194041 DOI: 10.1038/s41586-021-03684-z |
0.342 |
|
| 2021 |
Ortega-Villa AM, Nason MC, Follmann D. The mechanistic analysis of founder virus data in challenge models. Statistics in Medicine. PMID 34111904 DOI: 10.1002/sim.9075 |
0.359 |
|
| 2021 |
Fleming TR, Nason M, Krause PR, Longini IM, Henao-Restrepo AM. COVID-19 vaccine trials: The potential for "hybrid" analyses. Clinical Trials (London, England). 17407745211018613. PMID 34041932 DOI: 10.1177/17407745211018613 |
0.338 |
|
| 2021 |
Corbett KS, Nason MC, Flach B, Gagne M, O' Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, McDanal C, Francica JR, Flynn B, Wu K, Choi A, et al. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. Biorxiv : the Preprint Server For Biology. PMID 33907752 DOI: 10.1101/2021.04.20.440647 |
0.373 |
|
| 2021 |
Ruckwardt TJ, Morabito KM, Phung E, Crank MC, Costner PJ, Holman LA, Chang LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Lin B, Bailer R, Chen M, ... ... Nason MC, et al. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. The Lancet. Respiratory Medicine. PMID 33864736 DOI: 10.1016/S2213-2600(21)00098-9 |
0.322 |
|
| 2021 |
Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, ... ... Nason M, et al. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of Internal Medicine. PMID 33844575 DOI: 10.7326/M20-8149 |
0.333 |
|
| 2021 |
Fleming TR, Krause PR, Nason M, Longini IM, Henao-Restrepo AM. COVID-19 vaccine trials: The use of active controls and non-inferiority studies. Clinical Trials (London, England). 1740774520988244. PMID 33535811 DOI: 10.1177/1740774520988244 |
0.335 |
|
| 2020 |
Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, Sahly HE, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, ... ... Nason M, et al. Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials. Medrxiv : the Preprint Server For Health Sciences. PMID 33336213 DOI: 10.1101/2020.12.14.20248137 |
0.307 |
|
| 2020 |
Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, ... ... Nason M, et al. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of Internal Medicine. PMID 33090877 DOI: 10.7326/M20-6169 |
0.332 |
|
| 2020 |
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, ... ... Nason MC, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. The New England Journal of Medicine. PMID 32722908 DOI: 10.1056/Nejmoa2024671 |
0.319 |
|
| 2020 |
Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN, Pelc RS, DeMaso CR, Ko SY, Fisher BE, Yang ES, Nair D, Foulds KE, Todd JP, Kong WP, ... ... Nason MC, et al. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Science Translational Medicine. 12. PMID 32522807 DOI: 10.1126/Scitranslmed.Aaw9066 |
0.375 |
|
| 2019 |
Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, Holman LA, Hickman SP, Berkowitz NM, Gordon IJ, Yamshchikov GV, Gaudinski MR, Kumar A, Chang LA, Moin SM, ... ... Nason MC, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science (New York, N.Y.). 365: 505-509. PMID 31371616 DOI: 10.1126/science.aav9033 |
0.335 |
|
| 2019 |
Kong R, Duan H, Sheng Z, Xu K, Acharya P, Chen X, Cheng C, Dingens AS, Gorman J, Sastry M, Shen CH, Zhang B, Zhou T, Chuang GY, Chao CW, ... ... Nason MC, et al. Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. Cell. 178: 567-584.e19. PMID 31348886 DOI: 10.1016/j.cell.2019.06.030 |
0.346 |
|
| 2019 |
Brody IB, Calcedo R, Connell MJ, Carnathan DG, Nason M, Lawson BO, Nega MT, Boyd S, Qin Q, Vanderford TH, Wilson JM, Wilson JM, Silvestri G, Betts MR. Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model. Pathogens & Immunity. 4: 1-20. PMID 30993250 DOI: 10.20411/pai.v4i1.241 |
0.377 |
|
| 2019 |
Kong R, Duan H, Sheng Z, Xu K, Acharya P, Chen X, Cheng C, Dingens AS, Gorman J, Sastry M, Shen CH, Zhang B, Zhou T, Chuang GY, Chao CW, ... ... Nason MC, et al. Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization Cell. 178: 567. DOI: 10.2210/Pdb6Osy/Pdb |
0.346 |
|
| 2017 |
Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, ... ... Nason M, et al. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. The New England Journal of Medicine. 377: 1438-1447. PMID 29020589 DOI: 10.1056/Nejmoa1614067 |
0.306 |
|
| 2017 |
Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, James ER, Billingsley PF, Gunasekera A, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, ... ... Nason MC, et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America. PMID 28223498 DOI: 10.1073/Pnas.1615324114 |
0.348 |
|
| 2016 |
Crank MC, Wilson EM, Novik L, Enama ME, Hendel CS, Gu W, Nason MC, Bailer RT, Nabel GJ, McDermott AB, Mascola JR, Koup RA, Ledgerwood JE, Graham BS. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). Plos One. 11: e0166393. PMID 27846256 DOI: 10.1371/Journal.Pone.0166393 |
0.391 |
|
| 2016 |
Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, ... ... Nason MC, et al. Rapid development of a DNA vaccine for Zika virus. Science (New York, N.Y.). PMID 27708058 DOI: 10.1126/Science.Aai9137 |
0.352 |
|
| 2016 |
Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, ... ... Nason MC, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine. PMID 27158907 DOI: 10.1038/Nm.4110 |
0.348 |
|
| 2016 |
Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. PMID 27120156 DOI: 10.1038/Nature17677 |
0.311 |
|
| 2016 |
Nason M. Statistics and logistics: Design of Ebola vaccine trials in West Africa. Clinical Trials (London, England). 13: 87-91. PMID 26768560 DOI: 10.1177/1740774515620612 |
0.308 |
|
| 2015 |
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, et al. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. Plos One. 10: e0136626. PMID 26332672 DOI: 10.1371/Journal.Pone.0136626 |
0.381 |
|
| 2015 |
Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D, ... Nason M, et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nature Communications. 6: 6565. PMID 25858157 DOI: 10.1038/Ncomms7565 |
0.396 |
|
| 2015 |
Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB. Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine. 33: 749-52. PMID 25454855 DOI: 10.1016/J.Vaccine.2014.10.017 |
0.356 |
|
| 2014 |
Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Human Vaccines & Immunotherapeutics. 10: 3446-54. PMID 25483691 DOI: 10.4161/Hv.34408 |
0.311 |
|
| 2014 |
Sarwar UN, Novik L, Enama ME, Plummer SA, Koup RA, Nason MC, Bailer RT, McDermott AB, Roederer M, Mascola JR, Ledgerwood JE, Graham BS. Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial. Plos One. 9: e106240. PMID 25264782 DOI: 10.1371/Journal.Pone.0106240 |
0.398 |
|
| 2014 |
Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. The Journal of Experimental Medicine. 211: 2061-74. PMID 25155019 DOI: 10.1084/Jem.20132494 |
0.352 |
|
| 2014 |
Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, ... ... Nason MC, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. Journal of Virology. 88: 12669-82. PMID 25142607 DOI: 10.1128/Jvi.02213-14 |
0.309 |
|
| 2014 |
Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, ... ... Nason MC, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 505: 502-8. PMID 24352234 DOI: 10.1038/Nature12893 |
0.412 |
|
| 2013 |
Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, ... ... Nason MC, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (New York, N.Y.). 341: 1359-65. PMID 23929949 DOI: 10.1126/Science.1241800 |
0.313 |
|
| 2013 |
Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR, Nason MC, Roederer M, Andrews CA, Maldarelli FM, Wiegand A, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. The Journal of Infectious Diseases. 207: 1829-40. PMID 23482645 DOI: 10.1093/Infdis/Jit098 |
0.405 |
|
| 2012 |
Cheng C, Wang L, Wang L, Gall JG, Nason M, Schwartz RM, McElrath MJ, DeRosa SC, Hural J, Corey L, Buchbinder SP, Nabel GJ. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. Plos One. 7: e33969. PMID 22496775 DOI: 10.1371/Journal.Pone.0033969 |
0.338 |
|
| 2012 |
Yamamoto T, Johnson MJ, Price DA, Wolinsky DI, Almeida JR, Petrovas C, Nason M, Yeh WW, Shen L, Roederer M, Rao SS, McDermott AB, Lefebvre F, Nabel GJ, Haddad EK, et al. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. Journal of Virology. 86: 5877-84. PMID 22419810 DOI: 10.1128/Jvi.00315-12 |
0.394 |
|
| 2012 |
Doria-Rose NA, Louder MK, Yang Z, O'Dell S, Nason M, Schmidt SD, McKee K, Seaman MS, Bailer RT, Mascola JR. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. Journal of Virology. 86: 3393-7. PMID 22258252 DOI: 10.1128/JVI.06745-11 |
0.317 |
|
| 2012 |
Cheng C, Wang L, Gall JGD, Nason M, Schwartz RM, McElrath MJ, DeRosa SC, Hural J, Corey L, Buchbinder SP, Nabel GJ. Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination Plos One. 7. DOI: 10.1371/annotation/805c32e9-70cf-4937-af15-e26de6a11e99 |
0.314 |
|
| 2011 |
Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W, Bundrant N, Koup RA, Bailer RT, Mascola JR, Nabel GJ, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. The Journal of Infectious Diseases. 203: 1396-404. PMID 21398392 DOI: 10.1093/Infdis/Jir054 |
0.342 |
|
| 2010 |
Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. Plos One. 5: e9015. PMID 20126394 DOI: 10.1371/Journal.Pone.0009015 |
0.344 |
|
| 2010 |
Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, Bhattacharya T, Migueles SA, Wyatt RT, Korber BT, Mascola JR, Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. Journal of Virology. 84: 1631-6. PMID 19923174 DOI: 10.1128/Jvi.01482-09 |
0.307 |
|
| 2010 |
Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, Duerr AC, Keefer MC, Graham BS, Nabel GJ. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. Journal of Virology. 84: 630-8. PMID 19846512 DOI: 10.1128/Jvi.00866-09 |
0.407 |
|
| 2009 |
Price DA, Asher TE, Wilson NA, Nason MC, Brenchley JM, Metzler IS, Venturi V, Gostick E, Chattopadhyay PK, Roederer M, Davenport MP, Watkins DI, Douek DC. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. The Journal of Experimental Medicine. 206: 923-36. PMID 19349463 DOI: 10.1084/Jem.20081127 |
0.331 |
|
| 2009 |
Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. Journal of Virology. 83: 188-99. PMID 18922865 DOI: 10.1128/Jvi.01583-08 |
0.314 |
|
| 2009 |
Ledgerwood JE, Novik L, Enama ME, Gordon IJ, Holman LA, Nason MC, Bailer RT, Roederer M, Koup RA, Mascola JR, Nabel GJ, Graham BS. P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011) Retrovirology. 6: P198. DOI: 10.1186/1742-4690-6-S3-P198 |
0.312 |
|
| 2008 |
Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, Styles D, DeTolla LJ, Panda A, Sorrell EM, Song H, Wan H, Ramirez-Nieto GC, Perez D, Nabel GJ. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. Plos One. 3: e2432. PMID 19293944 DOI: 10.1371/Journal.Pone.0002432 |
0.334 |
|
| 2008 |
Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 26: 6338-43. PMID 18824060 DOI: 10.1016/J.Vaccine.2008.09.026 |
0.315 |
|
| 2007 |
Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. The Journal of Infectious Diseases. 196: 1732-40. PMID 18190252 DOI: 10.1086/523650 |
0.33 |
|
| 2007 |
Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR, Nabel GJ, Graham BS. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 25: 4085-92. PMID 17391815 DOI: 10.1016/J.Vaccine.2007.02.050 |
0.367 |
|
| 2006 |
Nason M. Patterns of immune response to a vaccine or virus as measured by intracellular cytokine staining in flow cytometry: hypothesis generation and comparison of groups. Journal of Biopharmaceutical Statistics. 16: 483-98. PMID 16892909 DOI: 10.1080/10543400600719426 |
0.335 |
|
| 2006 |
Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological Sciences : An Official Journal of the Society of Toxicology. 91: 610-9. PMID 16569729 DOI: 10.1093/Toxsci/Kfj169 |
0.354 |
|
| Show low-probability matches. |